ClinicalTrials.gg
Not yet recruitingNCT07292740Updated Dec 18, 2025

Arthroscopic Subscapularis Augmentation

An observational study in Shoulder Dislocation, sponsored by Al-Azhar University. Not yet recruiting. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Al-Azhar University · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The glenohumeral joint is the most commonly dislocated joint of the human body, The stability of GH joint relies on a complex network of static and dynamic structures.

Static stabilizers ::

Read the detailed description

The glenohumeral joint is the most commonly dislocated joint of the human body, The stability of GH joint relies on a complex network of static and dynamic structures.

Static stabilizers ::

  • include the congruency of the humeral head and glenoid, the glenoid labrum, glenohumeral ligaments surrounding the joint, and negative intra-articular pressure.

Dynamic stabilizers:

are primarily muscular and include the rotator cuff, which provides a compressive stabilizing effect, the tendon of the long head of the biceps, and muscles that stabilize the scapula ,The anterior labrum plays a key role in antero posterior stability as it deepens the glenoid cavity up to 50%.

anterior dislocation is the most common dislocation and is caused by the arm being positioned in an excessive amount of abduction and external rotation.

There are different methods of management

Can be achieved by several surgical techniques, according to whether the underlying etiology is a labral tear (Bankart) , humeral head lesion (Hill- Sachs) , or glenoid bone defect

Traumatic anterior shoulder instability without glenoid bone loss can be successfully treated with Bankart repair . On the other hand, bony procedures such as the Bristow and Latarjet procedures offer better outcomes in cases with concomitant glenoid bone loss greater than 21%-25% and engaging Hill-Sachs lesions

Controversy still exists regarding the ideal surgical treatment for AGI with limited (0%-13.5%) to subcritical (13.5%-25%) glenoid bone loss . Bony procedures are correlated with low recurrence, but high complication rates . On the contrary, clinical studies documented low complication rates [9], but higher recurrence rates or unsatisfactory outcomes for isolated or augmented Bankart repair in the context of subcritical glenoid bone loss

02

Conditions studied

  • Shoulder Dislocation

Browse trials for

03

In context

Shoulder Dislocation

105 studies on the registry are indexed under Shoulder Dislocation; 22 are open to participants now.

This study's planned enrollment of 20 is below the median of 86 across 28 observational studies indexed under Shoulder Dislocation.

Browse Shoulder Dislocation studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All patients were placed in the beach chair position after administration of general anesthesia or Regional anesthasia Diagnostic arthroscopy of the glenohumeral joint was The first step in accurate portal placement about the shoulder girdle is an identification of the subcutaneous anatomic landmarks; the scapular spine, acromial borders, AC joint, clavicle, and the coracoidprocess should b clearly identified. The posterior portal site can be localized as the (soft spot) in the triangular region between acromion, glenoid, andhumeral head; this point is variable but approximately 2 cm medial and 2 to 3 cm distal to the posterolateralcorner of the acromion

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patients complaining of anterior glenoid instability , with 1 or more episodes of anterior shoulder dislocation.

    2. Associated limited (\<13.5%) to subcritical (\<25%) glenoid bone loss. 3. Positive anterior shoulder apprehension and pain to conservative treatment.

    4. Age between (15 -49)years old

Exclusion criteria

Exclusion Criteria:

  • 1. Preexisting glenohumeral osteoarthritis, Infection 2. Multidirectional or voluntary shoulder instability. 3.. Acute proximal humerus fractures of the involved shoulder. 4.. refusable of patient
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Rowe score

    Assessment of the post operative and preoperative status of shoulder dislocation

    Time frame: 2nd and 6th months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Dodson CC, Cordasco FA. Anterior glenohumeral joint dislocations. Orthop Clin North Am. 2008 Oct;39(4):507-18, vii. doi: 10.1016/j.ocl.2008.06.001. PubMed 18803980 ↗
  • Zhang M, Liu J, Jia Y, Zhang G, Zhou J, Wu D, Jiang J, Yun X. Risk factors for recurrence after Bankart repair: a systematic review and meta-analysis. J Orthop Surg Res. 2022 Feb 20;17(1):113. doi: 10.1186/s13018-022-03011-w. PubMed 35184753 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07292740
Responsible party
Abdellah Ammar Abdellah Morsy (principal investigator, Al-Azhar University) — Principal investigator
First posted
Dec 18, 2025
Start date
Jan 1, 2026 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Dec 18, 2025

Study contacts

Abdellah Ammar Abdellah Morsy, MD
Contact
bebobebo1093@gmail.com
0201023755016
Hosam Elsayed Abd-Elzaher, MD
Contact
hosamortho@gmail.com
0201008832805

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion